Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
10592studies shown
Showing 8,761-8,772 of 10,592
Drug study icon
CompletedNCT00202605

Safety and Efficacy of SPD465 in Adults With ADHD

This study exists to compare options and see whether this type of care offers something meaningfully different. Researchers are trying to understand what this type of care could change in day-to-day care and decision-making.

In United States
ADHDDrugA study involving a medication or substance.From 18 Years to 55 Years
Countries
United States
Sponsor
Shire
Condition
ADHD
Drug study icon
TerminatedNCT00257192

Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In United States
SchizophreniaDrugFrom 13 Years to 17 Years
Countries
United States, Colombia, Costa Rica, ...
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Condition
Schizophrenia
Drug study icon
CompletedNCT00257166

Safety and Efficacy of Ziprasidone in Children and Adolescents With Bipolarity type I (Manic or Mixed)

This study exists to explore whether a medication treatment could improve care and understanding. Researchers are trying to understand what a medication treatment could change in day-to-day care and decision-making.

In United States
BipolarityDrugFrom 10 Years to 17 Years
Countries
United States
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Condition
Bipolarity
Drug study icon
CompletedNCT02547428

Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

This study exists to compare options and see whether the medication Centanafadine offers something meaningfully different. Researchers are trying to understand how people respond to the medication Centanafadine in practice and what may need to be adjusted.

In United States
ADHDDrugFrom 18 Years to 60 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
ADHD
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.